article_metadata: Wenqi Zhang Chen Huang Ruixia Liu Huichao Zhang Weijing Li Shaoning Yin Lianjing Wang Wei Liu Lihong Liu
article_metadata: 10.3389/fimmu.2022.983934
article_metadata: Front Immunol
article_metadata: 2022 Oct 5;13:983934.
article_metadata: btk inhibitor cd19 car-t cell therapy pd-1 antibody scnsl tislelizumab zanubrutinib
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/36275715/
article_metadata: Central Nervous System Neoplasms / pathology Central Nervous System Neoplasms / therapy Lymphoma, Large B-Cell, Diffuse / pathology Neoplasms, Second Primary Receptors, Chimeric Antigen
article_metadata: Central Nervous System Neoplasms / pathology Central Nervous System Neoplasms / therapy Lymphoma, Large B-Cell, Diffuse / pathology Neoplasms, Second Primary Receptors, Chimeric Antigen Case Reports Research Support, Non-U.S. Gov't Antigens, CD19 Cell- and Tissue-Based Therapy Central Nervous System Clinical Trials as Topic Female Humans Neoplasm Recurrence, Local / drug therapy Programmed Cell Death 1 Receptor Protein Kinase Inhibitors / therapeutic use Antigens, CD19 Programmed Cell Death 1 Receptor Protein Kinase Inhibitors Receptors, Chimeric Antigen
article_metadata: PMC9581047
article_metadata: 36275715
article_metadata: Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
article_metadata: 2022